Suppr超能文献

单次服用含肠溶微胶囊的混悬液后布洛芬的药代动力学。

Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules.

作者信息

Walter K, Weiss G, Laicher A, Stanislaus F

机构信息

Klinge Pharma GmbH, Munich, Germany.

出版信息

Arzneimittelforschung. 1995 Aug;45(8):886-90.

PMID:7575754
Abstract

The relative bioavailability of ibuprofen (CAS 15687-27-1) was investigated following a single administration of a suspension containing enteric-coated microcapsules (A) in comparison to a rapid-release film-coated tablet (B) and a sustained-release tablet (C). The study was carried out in a three-way crossover design in 9 healthy male volunteers. Each formulation contained 800 mg ibuprofen. Plasma concentrations of ibuprofen were determined with a specific HPLC method. A mean relative bioavailability of 0.96 (B) and 1.01 (C) was determined for the test formulation. Since the corresponding 90% confidence intervals were within the recommended limits, bioequivalence for the extent of bioavailability of the test formulation can be concluded. Differences in pharmacokinetics were observed for the rate-dependent parameters. For the test formulation, the highest mean maximum plasma concentration (54.3 micrograms/ml) was measured with a corresponding tmax of 1.9 h. For the reference formulations, mean peak plasma concentrations of 45.2 micrograms/ml after 2.6 h (B) and 25.7 micrograms/ml after 5.6 h (C) were observed. Despite the enteric coating of the microcapsules, a very short lagtime of 0.03 h was determined for the suspension. For the other rapid release formulation (B), the lagtime was in a similar magnitude (0.11 h), while the absorption from the sustained-release tablet was clearly decelerated (tlag = 0.97 h). In comparison to the other rapid-release formulation (B), significant higher amounts of the drug were absorbed from the test formulation (A) within the first hour.

摘要

在单次给予含肠溶包衣微胶囊的混悬液(A)后,与速释薄膜包衣片(B)和缓释片(C)相比,研究了布洛芬(CAS 15687-27-1)的相对生物利用度。该研究采用三交叉设计,在9名健康男性志愿者中进行。每种制剂均含有800mg布洛芬。采用特定的高效液相色谱法测定血浆中布洛芬的浓度。测定了受试制剂的平均相对生物利用度为0.96(B)和1.01(C)。由于相应的90%置信区间在推荐范围内,因此可以得出受试制剂生物利用度程度的生物等效性结论。观察到速率依赖性参数的药代动力学差异。对于受试制剂,测得的最高平均最大血浆浓度为54.3微克/毫升,相应的达峰时间为1.9小时。对于参比制剂,观察到在2.6小时后平均峰血浆浓度为45.2微克/毫升(B),在5.6小时后为25.7微克/毫升(C)。尽管微胶囊有肠溶包衣,但该混悬液的滞后时间非常短,为0.03小时。对于另一种速释制剂(B),滞后时间在相似范围内(0.11小时),而从缓释片中的吸收明显减慢(滞后时间=0.97小时)。与另一种速释制剂(B)相比,在第一小时内从受试制剂(A)中吸收的药物量显著更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验